Description of the medicine: Tirofiban (Tirofiban)
N- (Butylsulfonyl) -4- [4- (4-piperidine) butoxy] -α-phenylalanine monohydrochloride monohydrate.
Synonym: Agrrastat, Aggrastate.
A non-peptidic blocker of glycoprotein IIb / IIIa receptors of reversible action (blockade of receptors last 4-6 hours after discontinuation of infusion compared to 10 days in abciximab).
The drug molecule imitates a tripeptide sequence in the fibrinogen structure that binds to the above receptor.
Apply (in combination with acetylsalicylic acid and heparin) to prevent myocardial infarction in patients with unstable angina.
Assign intravenously infusion first at a rate of 0.4 μg / kg per minute for 30 minutes, then 0.1 μg / kg per minute for at least 48 hours; Maximum duration of infusion 108 h.
Possible side effects are the same as in eptifibatide.
Contraindications and precautions are the same as with abciximab.
Form release: 0.025% concentrate for infusion solutions in bottles of 50 ml.